Abstract
Introduction Shoe modification and orthotics play an important role in non-operative management for 1st metatarsophalangeal (MTP) arthritis. However, compliance can be low due to pain and discomfort. We hypothesized that patients who wear a flexible carbon fiber insole for 1st metatarsophalangeal arthritis will report reduced pain, and higher physical function and compliance rate when compared with a rigid Morton’s extension insole.
Methods Four males and nine females (mean age of 56 years; range 35-79) diagnosed with 1st metatarsophalangeal arthritis were included in this randomized controlled trial. Participants randomly received either bilateral flexible carbon fiber insoles (VKTRY®) (n=7) or unilateral Morton’s extension insole (n=6). Outcome measures included patient compliance, comfort rate, and Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaires Global Health, pain interference, v1.0 pain intensity, v2.0 Physical Function, and v1.0 Depression. Participants filled out questionnaires at baseline and at two, six, and twelve weeks follow-up.
Results Compared to Morton’s extension insole, use of flexible carbon fiber insole led to reduction of pain interference score at 6 and 12 weeks (median ⍰ −9.5 vs 0.0 p=0.015; and median ⍰ −15.1 vs −2.3 p=0.015, respectively), as well as reduction of pain intensity score at 6 and 12 weeks (median ⍰ −11.9 vs −2.3 p=0.018; and median ⍰ −11.9 vs −2.3 p=0.010, respectively). The compliance rate in flexible carbon fiber insole group was 100% at 2, 6 and 12 weeks, compared to 83%, 83% and 50% in the Morton group. In addition, patients wearing carbon fiber insoles experienced higher comfort levels (p-values ranging from <0.001 to p=0.007). There were no differences between the comparison groups at 2, 6, and 12 weeks in terms of the global health, physical function, and depression scores.
Conclusion Patients diagnosed with 1st metatarsophalangeal arthritis may benefit from wearing flexible carbon fiber insoles, compared to commonly used rigid orthotic insoles, such as the Morton’s extension. This insert can be used safely for nonoperative treatment of hallux rigidus and is another option for nonoperative treatment.
LEVEL OF EVIDENCE Level I, randomized clinical trial.
Competing Interest Statement
Dr. Waryasz reports non-financial support from VKTRY, Inc., during the conduct of the study; non-financial support from Arthrex, Inc, outside the submitted work; and American Orthopaedic Foot and Ankle Society: Board or committee member. Dr. DiGiovanni reports non-financial support from Arthrex, Inc, non-financial support from Butterfly Network, non-financial support from OrthoScan, Inc, outside the submitted work; and American Orthopaedic Foot and Ankle Society: Board or committee member, Foot and Ankle International: Editorial or governing board, Foot and Ankle Orthopaedics: Editorial or governing board, Techniques in Orthopaedics: Editorial or governing board. Dr. Guss reports non-financial support Arthrex, Inc, non-financial support from Butterfly Network, non-financial support from Orthoscan, other from AOFAS/DJO Traveling Fellowship, other from Wright Medical Technology, Inc., outside the submitted work; and American Orthopaedic Foot and Ankle Society: Board or committee member. Dr. Lubberts reports non-financial support from Arthrex, Inc, non-financial support from Butterfly Network, outside the submitted work; and Orthopaedic Research Society: Board or committee member. The other authors declare that they have no conflict of interest.
Clinical Trial
NCT04833608
Funding Statement
This research received non-financial research support from VKTRY·inc, including the flexible carbon fiber insoles and the rigid Mortons extension insole.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Mass General Brigham IRB (IRB Protocol #: 2018P002864).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data generated or analysed during this study are included in this published article
